NRIX News and Press, Nurix Therapeutics Inc. From 03/19/23

2023-03-19 23:39:45 ET Summary NRIX announced early data at ASH last year. The company has a couple of major partnerships. They have a decent cash runway. Nurix Therapeutics ( NRIX ) works in the field of targeted protein degradation in order to attack cancer cells. ...

SAN FRANCISCO, March 06, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that Arthur T. Sands, M.D.,...

Nurix Therapeutics press release ( NASDAQ: NRIX ): Q4 GAAP EPS of -$0.87 misses by $0.10 . Revenue of $6.78M (-8.4% Y/Y) misses by $10.39M . For further details see: Nurix Therapeutics GAAP EPS of -$0.87 misses by $0.10, revenue of $6.78M misses by $10.39M

Demonstrated NX-2127 overcomes BTK inhibitor resistance mutations and provides clinical benefit to patients with hematological malignancies Achieved significant milestones in wholly owned clinical programs and partnered preclinical programs Maintained strong financial position w...

The following slide deck was published by Nurix Therapeutics, Inc. in conjunction with this event. For further details see: Nurix Therapeutics (NRIX) Presents At 41st Annual Healthcare Conference - Slideshow

Nurix leads targeted protein modulation field with its wholly owned clinical stage programs and two strategic collaborations fueled by its DELigase platform Clinical data updates planned for Nurix’s two first-in-class BTK degraders in 2023 Clinical data update planned for...

Summary Baker Brothers’ 13F portfolio value decreased from $17.63B to $15.27B this quarter. Rhythm Pharma and Akero Therapeutics were increased while decreasing argenx SE and Horizon Therapeutics. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they a...

SAN FRANCISCO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that Arthur T. Sands, M.D., ...

NX-5948 is being evaluated in patients with relapsed and refractory B-cell malignancies Phase 1 clinical trial now enrolling patients in the United Kingdom with plans to expand to clinical sites in the United States SAN FRANCISCO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeu...

Treatment with NX-2127 provides clinically meaningful responses in heavily pretreated chronic lymphocytic leukemia (CLL) patients regardless of Bruton’s tyrosine kinase ( BTK) mutational status BTK mutations conferring resistance to both covalent and non-covalent BTK inhibito...